Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

I-131-Apamistamab - Actinium Pharmaceuticals

Drug Profile

I-131-Apamistamab - Actinium Pharmaceuticals

Alternative Names: 131-I-labeled anti-CD45 antibody; 131-I-labeled BC8 antibody; 131I-BC8 (anti-CD45) antibody - Actinium Pharmaceuticals; Anti-CD45 monoclonal antibody-BC8-I-131; Anti-CD45 monoclonal antibody-I-131; BC 8; BC8-I-131 construct; I131-Apamistamab; Iodine-131-apamistamab; Iomab-ACT; Iomab-B

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Actinium Pharmaceuticals; Fred Hutchinson Cancer Research Center
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
  • No development reported Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 06 Nov 2019 Additional efficacy and pharmacokinetics data from the phase III SIERRA trial in Acute myeloid leukaemia released by Actinium Pharmaceuticals
  • 06 Nov 2019 Actinium Pharmaceuticals plans a first-in-man clinical trial of I-131-Apamistamab in conjunction with a CAR-T therapy
  • 28 Apr 2019 No recent reports of development identified for phase-I development in Hodgkin's-disease(Refractory metastatic disease, Second-line therapy or greater) in USA (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top